{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:14:50Z","timestamp":1793754890804,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fjurol.2025.103007","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:29:33Z","timestamp":1760660973000},"page":"103007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updated 2025 French guidelines for renal cell carcinoma"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-9020","authenticated-orcid":false,"given":"Pierre","family":"Bigot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zine-Eddine","family":"Khene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Correas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-602X","authenticated-orcid":false,"given":"St\u00e9phane","family":"De Vergie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Doumerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Ferragu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Ingels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-1597","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Margue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idir","family":"Ouza\u00efd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pettenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-7510","authenticated-orcid":false,"given":"Nathalie","family":"Rioux-Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-479X","authenticated-orcid":false,"given":"Thibaut","family":"Waeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.103007_bib0185","unstructured":"Cancer Today n.d. https:\/\/gco.iarc.who.int\/today\/ [accessed 29 September 2025]."},{"key":"10.1016\/j.fjurol.2025.103007_bib0190","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2025.103007_bib0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of renal cancer: incidence, mortality, survival, genetic predisposition, and risk factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0205","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","article-title":"Epidemiology and screening for renal cancer","volume":"36","author":"Rossi","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bju.16260","article-title":"Short-term psychosocial outcomes of adding a non-contrast abdominal computed tomography (CT) scan to the thoracic CT within lung cancer screening","volume":"133","author":"Usher-Smith","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.103007_bib0215","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.eururo.2024.08.029","article-title":"Abdominal noncontrast computed tomography scanning to screen for kidney cancer and other abdominal pathology within community-based computed tomography screening for lung cancer: results of the Yorkshire Kidney Screening Trial","volume":"87","author":"Stewart","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euros.2025.01.016","article-title":"Renal mass biopsy prior to surgical excision: practice, diagnostic performance, and impact on management in the UroCCR Registry (Ancillary Study No. 118)","volume":"73","author":"Proye","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2025.103007_bib0225","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bju.16885","article-title":"Biopsy-all strategy in patients with a renal mass: simulation of a randomised controlled trial","volume":"136","author":"Belladelli","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.103007_bib0230","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.euo.2024.09.001","article-title":"Frailty and renal cell carcinoma: integration of comprehensive geriatric assessment into shared decision-making","volume":"8","author":"Pecoraro","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.eururo.2025.03.002","article-title":"Longitudinal evaluation of clear-cell renal cell carcinoma in von Hippel-Lindau Disease","volume":"88","author":"Linehan","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0240","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study","volume":"26","author":"Srinivasan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.08.007","article-title":"Defining the histopathological, clinical, and genetic characteristics of familial BAP1-associated renal cell carcinoma","author":"Posada Calderon","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0250","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.euo.2025.01.013","article-title":"Hospital volume as a determinant of outcomes after partial nephrectomy: a systematic review by the european association of urology renal cell carcinoma guidelines panel","volume":"8","author":"Marconi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0255","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.14848","article-title":"Impact of hospital nephrectomy volume on intermediate- to long-term survival in renal cell carcinoma","volume":"125","author":"Hsu","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.103007_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2025.05.048","article-title":"Characterising the hospital caseload-outcome relationship for radical nephrectomy with inferior vena cava tumor thrombectomy: analysis from the National Inpatient Sample","author":"Henning","year":"2025","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2025.103007_bib0265","unstructured":"Decree No. 2022-689 of 26 April 2022 on the conditions for establishing cancer treatment activities. 2022."},{"key":"10.1016\/j.fjurol.2025.103007_bib0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/JU.0000000000004583","article-title":"Active surveillance vs. primary intervention for clinical T1a kidney tumours: 12-year experience of the delayed intervention and surveillance for small renal masses prospective comparative study","volume":"214","author":"Alkhatib","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0275","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/JU.0000000000003158","article-title":"Pathological and clinical outcomes in a large surveillance and intervention cohort of radiographically cystic renal masses","volume":"209","author":"Lee","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0280","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0285","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.103007_bib0290","article-title":"Efficacy of SABR in uncommon subtypes of primary kidney cancer: an analysis from the International Radiosurgery Oncology Consortium of the Kidney","author":"Ali","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2025.103007_bib0295","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(24)00731-9","article-title":"Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis","volume":"26","author":"Huang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euros.2025.07.003","article-title":"Determining the impact of histology on the incidence, pattern, and timing of recurrences in patients with Renal Cell Carcinoma: A pooled analysis from the SORCE and ASSURE trials","volume":"79","author":"Oza","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2025.103007_bib0305","article-title":"Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis","author":"Tundealao","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0310","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2025.05.014","article-title":"The nephrologist's perspective in evaluation and management of localised renal masses: core curriculum 2025","author":"Tillquist","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.fjurol.2025.103007_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","author":"Steiner","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2025.103007_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.07.011","article-title":"Urine Glycosaminoglycan Scores for Surveillance of recurrence in intermediate- and high-risk nonmetastatic clear cell renal cell carcinoma\u2014An observational prospective multicentre diagnostic test cohort study","author":"Dabestani","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0325","doi-asserted-by":"crossref","first-page":"105323","DOI":"10.1016\/j.esmoop.2025.105323","article-title":"Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay","volume":"10","author":"Peng","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.fjurol.2025.103007_bib0330","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oncolo\/oyae180","article-title":"Association of circulating tumour DNA with patient prognosis in surgically resected renal cell carcinoma","volume":"29","author":"Correa","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.fjurol.2025.103007_bib0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.103007_bib0340","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.103007_bib0345","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2024.07.016","article-title":"First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma: an international multicenter study","volume":"86","author":"El Zarif","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0350","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.fjurol.2025.103007_bib0355","doi-asserted-by":"crossref","first-page":"1202822","DOI":"10.3389\/fimmu.2023.1202822","article-title":"Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.fjurol.2025.103007_bib0360","article-title":"et al.Late-onset immune-related adverse events after immune checkpoint inhibitor therapy JAMA Netw","volume":"8","author":"Durbin","year":"2025","journal-title":"Open"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:19Z","timestamp":1790178379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025001548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950393025001548"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103007","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated 2025 French guidelines for renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103007"}}